Alerta

USE OF PLACENTA HOMINIS IN PREPARATION OF ANTI-CANCER DRUG

Resumen de: WO2026030836A1

Use of Placenta Hominis in the preparation of an anti-cancer drug. Water extraction is one of extraction methods for Placenta Hominis. Placenta Hominis can treat various cancers, such as lymphoma, leukemia, skin cancer, lung cancer, breast cancer, liver cancer, gastric cancer, pancreatic cancer, rectal cancer, brain cancer, kidney cancer, bladder cancer, etc., by improving human immunity.

BCL6 INHIBITORS

Resumen de: US20260042776A1

The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity:wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

USE OF UTIDELONE IN TREATMENT OF SOLID TUMORS

Resumen de: WO2026032322A1

Disclosed in the present application is the use of a compound of formula I in the preparation of a drug for treating the following tumors, which are selected from gastric cancer, esophageal cancer, cholangiocarcinoma, nasopharyngeal cancer, soft tissue sarcoma, prostate cancer, liver cancer, non-small cell lung cancer, breast cancer, glioma, leukemia, ovarian cancer, cervical cancer, endometrial carcinoma, primary brain tumors, brain metastatic tumors, pancreatic cancer and angiosarcoma. Further disclosed is the use of the compound in combination with other anti-tumor drugs in the treatment of the above-mentioned cancers.

CD70 BINDING MOLECULES AND METHODS OF USE THEREOF

Resumen de: EP4692125A2

The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Resumen de: US20260034176A1

The present disclosure provides, among other things, methods for treating relapsed or refractory acute myeloid leukemia by administering to a subject in need thereof a therapeutically effective amount of an allogeneic composition comprising VDelta1+ (Vδ1+) gamma delta (γδ) T cells such that one or more symptoms or biomarkers is improved after treatment. The present disclosure also provides suitable doses of compositions comprising allogeneic Vδ1+gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, the Vδ1+gamma delta (γδ) T cells are untransduced.

CELLS, METHOD FOR DETECTING PYROGENIC SUBSTANCE IN SPECIMEN, AND KIT FOR USE IN DETECTING PYROGENIC SUBSTANCE

Resumen de: EP4692331A1

An object of the present invention is to provide a novel cell used for detecting a pyrogenic substance by a MAT method, a method of detecting a pyrogenic substance in a specimen using the cell, and a kit for use in detecting a pyrogenic substance, containing the cell. According to the present invention, there are provided a cell which is derived from any one of a promonocyte-like cell line NOMO-1, a human-derived monocyte cell line U-937, a human-derived monoblast cell line GDM-1, a human-derived monocyte/macrophage cell line 28SC-ES, or a multiple myeloma cell line RPMI8226, in which at least one reporter gene, expression of which is controlled by a promoter inducible by NF-κB, has been introduced into the cell, and the cell has a toll-like receptor; a method for detecting a pyrogenic substance in a specimen using the cell; and a kit for use in detecting a pyrogenic substance, containing the cell.

USE OF DRUG COMBINATION CONTAINING ANTI-CD20 ANTIBODY-DRUG CONJUGATE IN PREPARATION OF DRUG FOR TREATING NHL

Resumen de: EP4691495A1

The present disclosure discloses a use of a drug combination containing an anti-CD20 antibody drug conjugate (ADC) in the preparation of a drug for treating Non-Hodgkin Lymphoma (NHL). The drug combination includes the anti-CD20 ADC and at least one therapeutic agent. The drug combination therapy has better efficacy than the existing clinical first-line standard therapy. Additionally, it offers several advantages, including fewer types of drugs, shorter infusion time, lower safety risks, and better economic accessibility.

COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS

Nº publicación: KR20260019669A 10/02/2026

Solicitante:

테른스파마슈티칼스인크

Resumen de: US2025276961A1

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.